Pharmaceutical Contaminant Removal Companies
Micropollutant removal, ozone, AOP, GAC, and NF for pharmaceuticals, hormones, and personal care products.
8 specialist providers · 30 related · 14 countries
Qualified suppliers come to you.
Filter results
Country
Industry
Technology
Not sure where to start?
Showing 1-20 of 38
Specialists in pharmaceutical contaminant removal
Providers whose services or self-declared specialties match this category.
BioProcess H2O
United States
bioprocessH2O is a United States company headquartered in Portsmouth, Rhode Island that designs, manufactures, and assembles advanced process water and wastewater treatment systems for industrial and municipal clients. The company specializes in custom-engineered systems for pharmaceutical and biotech wastewater, managing organic compounds, heavy metals, ammonia, and dissolved solids while supporting regulatory compliance and operational efficiency.
Related providers
Listed for overlapping capabilities, not for pharmaceutical contaminant removal specifically.
Hangzhou Realize Technology Co., LTD.
VerifiedChina · 1-50 employees · 1 case study
HANGZHOU REALIZE TECHNOLOGY CO., LTD. is a technology enterprise. The company collaborates with domestic and international universities such as Beijing University of Technology, Tsinghua University, and Berlin University of Technology to address the challenges of enhancing anaerobic efficiency and nitrogen removal in high-ammonia nitrogen wastewater. The core technologies foucs on energy-saving denitrification and enhanced green methane production. These two technologies can increase production efficiency of green methane by 20% and reduce costs of wastewater denitrification by 60%.
Buyer's guide
The buyer's guide to pharmaceutical contaminant removal
Pharmaceutical and Micropollutant Removal: Ozonation, Advanced Oxidation, and Activated Carbon
Pharmaceuticals and personal care products (PPCPs) are classified as contaminants of emerging concern (CECs) detected in surface water at concentrations of 1 to 1,000 ng/L and in treated drinking water at 0.1 to 100 ng/L. Key compounds: carbamazepine (epilepsy drug, highly persistent, 0.001 to 10 ug/L in wastewater effluent); diclofenac (anti-inflammatory, EU WFD priority substance at EQS of 0.1 ug/L in freshwater); 17-alpha-ethinylestradiol (EE2, synthetic oestrogen, EQS 0.035 ng/L); ibuprofen, metformin, antibiotics (ciprofloxacin, erythromycin), and X-ray contrast media (iopromide).
Conventional drinking water treatment (coagulation, sedimentation, filtration, chlorination) removes 20 to 60 percent of most pharmaceuticals. Ozonation at doses of 0.5 to 1.0 mg O3 per mg DOC removes 70 to 99 percent of ozone-reactive pharmaceuticals (carbamazepine greater than 99 percent, ibuprofen greater than 95 percent, EE2 greater than 95 percent) but produces transformation products requiring biological post-filtration.
Advanced oxidation processes (AOPs) combining ozone with hydrogen peroxide (O3/H2O2, peroxone process) or UV with H2O2 generate hydroxyl radicals (OH radical, rate constant 10 to the 8 to 10 to the 10 M-1 s-1) capable of mineralising ozone-resistant compounds. O3/H2O2 at H2O2:O3 molar ratio of 0.5:1 improves removal of iopromide and NDMA precursors compared to ozone alone. UV/H2O2 at UV dose 500 to 1,000 mJ/cm2 with H2O2 of 10 to 20 mg/L achieves greater than 90 percent removal of carbamazepine and EE2.
Photocatalysis (UV/TiO2) and Fenton-based systems are effective at lab scale but have limited full-scale implementation due to catalyst management challenges. Biological activated carbon (BAC) - ozone followed by activated carbon with biological activity - combines adsorption and biodegradation: achieving 80 to 95 percent overall PPCP removal in European drinking water treatment plants (e.g. Netherlands WRK, Germany Bodensee plants).
EU regulatory context: EU Drinking Water Directive 2020/2184 requires member states to undertake watch-list monitoring of emerging contaminants including pharmaceuticals. The EU Water Framework Directive Environmental Quality Standards Directive (2013/39/EU) sets EQS for diclofenac (0.1 ug/L), EE2 (0.035 ng/L), and E2 (0.04 ng/L) in surface water. UK: post-Brexit, UK retained these values within the UK WFD.
US: EPA has not set enforceable MCLs for pharmaceuticals in drinking water; they appear on the Contaminant Candidate List (CCL5, 2022) and Unregulated Contaminant Monitoring Rule (UCMR5, 2021-2025) requiring monitoring at systems serving greater than 3,300 people. WHO drinking water guidelines (2022) cover selected pharmaceuticals including carbamazepine and ibuprofen with health-based screening values. Hospital and pharmaceutical manufacturing wastewater is the dominant point source; pre-treatment standards are being tightened under IED (Industrial Emissions Directive) revisions.
Frequently asked questions
Are pharmaceuticals regulated in drinking water?
In the EU: no current specific MCLs for individual pharmaceuticals in drinking water, but the DWD 2020/2184 introduces a watch list and minimum monitoring requirements, and member states must assess risk. EU WFD EQS apply to diclofenac (0.1 ug/L), EE2 (0.035 ng/L), and E2 (0.04 ng/L) in surface water bodies - these indirectly drive drinking water source protection. In the US: EPA has set no enforceable MCLs for pharmaceuticals; UCMR5 (2021-2025) requires monitoring of 29 PFAS and some other CECs but not yet pharmaceuticals; CCL5 (2022) includes several pharmaceuticals under evaluation. UK: follows transposed WFD values for surface water EQS; no specific drinking water MCLs. Australia: NHMRC Australian Drinking Water Guidelines (2022 revision) include guidance values for selected pharmaceuticals. Current regulatory trajectory suggests enforceable limits are likely within the next 5 to 10 years.
Does ozonation remove all pharmaceuticals?
Ozonation effectively removes ozone-reactive pharmaceuticals (those with electron-rich moieties: phenols, anilines, double bonds) but is less effective for ozone-resistant compounds. High removal (greater than 90 percent) at standard doses (0.5 to 1.0 mg O3 per mg DOC): carbamazepine, EE2, diclofenac, naproxen, bezafibrate, sulfamethoxazole. Moderate removal (50 to 90 percent): ibuprofen, trimethoprim, metronidazole. Poor removal (less than 50 percent): iopromide, TCEP, some X-ray contrast media, metformin. For ozone-resistant compounds, AOP (O3/H2O2 or UV/H2O2) is required. Importantly, ozonation produces biodegradable transformation products (aldehydes, keto-acids) and can form bromate (BrO3-) in bromide-rich waters - maximum 10 ug/L bromate per EU DWD and US EPA MCL. Biological filtration after ozonation (BAC) mineralises transformation products and provides additional pharmaceutical removal.
What pharmaceutical removal is achieved by activated carbon?
Powdered activated carbon (PAC) dosed at 5 to 20 mg/L achieves 50 to 80 percent removal of most pharmaceuticals in a single pass; increasing to 20 to 40 mg/L approaches 90 percent for high-affinity compounds (carbamazepine, diclofenac). Granular activated carbon (GAC) at EBCT of 10 to 15 minutes achieves greater than 90 percent removal initially, declining as carbon exhausts - breakthrough depends on compound hydrophobicity (log Kow) and molecular weight. GAC beds are effective for carbamazepine (log Kow 2.45), diclofenac (log Kow 4.51), and EE2 (log Kow 3.67) but less effective for hydrophilic compounds (metformin, NDMA). Biological activated carbon (GAC with biofilm) combines adsorption and biodegradation, extending effective removal life. Full-scale Swiss experience (post-2020 micropollutant ordinance) shows ozone plus GAC achieving 80 to 90 percent removal across a broad pharmaceutical spectrum at approximately EUR 0.10 to 0.20 per m3 incremental cost.
How do hospital wastewaters contribute to pharmaceutical contamination?
Hospitals are recognised as point sources of elevated pharmaceutical concentrations. Hospital wastewater concentrations: antibiotics at 10 to 1,000 times higher than municipal wastewater; cytostatics (cyclophosphamide, ifosfamide) at 10 to 500 ug/L (genotoxic concern); iodinated X-ray contrast media at 100 to 10,000 ug/L. Hospital wastewater typically represents 0.1 to 1 percent of municipal wastewater flow but may contribute 10 to 30 percent of pharmaceutical load. EU Industrial Emissions Directive (IED) recast (2022) and revision proposals aim to include hospitals in regulated sectors with pharmaceutical pre-treatment requirements. Best practice: on-site ozonation or membrane bioreactor (MBR) treatment before discharge achieves 90 to 99 percent pharmaceutical removal. Switzerland's water protection ordinance requires pharmaceutical manufacturers to treat wastewater to achieve 80 percent micropollutant removal. Germany's Abwasserverordnung (Wastewater Ordinance, Annex 22) sets specific requirements for pharmaceutical industry effluent.
Illustrative scenario · UK water company, advanced treatment upgrade, Thames Valley
A composite drawn from typical projects in this category, not a single client engagement. Figures are indicative.
- Challenge
- Source water monitoring detected carbamazepine at 85 ng per L, diclofenac at 120 ng per L, and EE2 at 0.06 ng per L in the river abstraction source, raising concerns ahead of anticipated EU DWD watch-list compliance requirements. The existing treatment train (coagulation, DAF, rapid gravity filtration, UV, chlorination) removed less than 30 percent of the detected pharmaceuticals.
- Approach
- A mid-point ozone stage (2.8 mg per L, target CT 0.5 mg per L-min) followed by GAC contactors (EBCT 15 minutes, coal-based GAC) was retrofitted between the rapid gravity filters and the UV system. H2O2 co-dosing at 0.5:1 molar ratio H2O2:O3 was included to improve iopromide removal. Bromate was managed by pH depression to 6.7 ahead of ozone and the bromide in the source was below 30 ug per L.
- Outcome
- Carbamazepine removal improved to 98 percent, diclofenac to 97 percent, and EE2 to 95 percent in the treated water. THM concentrations fell 38 percent as ozone pre-oxidised NOM precursors. DWI approved the treatment configuration modification. Bromate remained below 3 ug per L throughout the first operational year.
Questions to ask shortlisted providers
5
- 01
What pharmaceutical compounds have been detected in the source water and at what concentrations?
Treatment technology selection depends on the specific compound profile; ozone-reactive pharmaceuticals (phenols, anilines) respond very differently from resistant compounds (iopromide, NDMA precursors) that require AOP.
- 02
What is the bromide concentration in the source water and is bromate formation risk management included in the ozone design?
Bromide above 20 ug per L creates significant bromate risk; pH depression, ammonia, or H2O2 co-dosing must be integrated into the design from the outset.
- 03
What EBCT is specified for the GAC stage and what is the projected service life before breakthrough?
GAC service life and replacement frequency determine OPEX; a pilot column study with site water should validate EBCT before full-scale design.
- 04
What monitoring regime will verify pharmaceutical removal performance on an ongoing basis?
LC-MS/MS pharmaceutical analysis costs 500 to 1,500 GBP per sample; the monitoring programme and alert thresholds must be agreed with DWI as part of the treatment approval.
- 05
Is any transformation product monitoring required and what is the ecological risk assessment for the receiving watercourse?
Ozonation produces transformation products (e.g. from diclofenac, iopromide) that may be more toxic than the parent compound; these must be assessed in the environmental impact evaluation.
What drives cost in this category
4
- Ozone system capacity and oxygen supply
- Mid-point ozone retrofits for a 20 to 50 MLD plant cost 1 to 4 million GBP including CD generators, PSA oxygen concentrator, contact tanks, and destruct units.
- GAC contactor civil works and carbon volume
- Converting existing RGF beds to GAC contactors is the most cost-effective approach; purpose-built GAC contactors add 500,000 to 3,000,000 GBP in civil costs for a medium-sized works.
- GAC replacement frequency and reactivation logistics
- At 15-minute EBCT and moderate pharmaceutical loading, GAC reactivation is required every 18 to 36 months; reactivation cost 600 to 1,000 GBP per tonne adds 0.03 to 0.08 GBP per m3 OPEX.
- Regulatory approval and pharmaceutical monitoring programme
- DWI approval of a new pharmaceutical treatment process requires independent validation, monitoring data, and DWI correspondence, typically adding 12 to 18 months and 80,000 to 200,000 GBP to the project.
Key regulations and standards
4
- EU DWD 2020/2184 Watch List and Pharmaceuticals
- Article 13 requires member states to monitor pharmaceuticals on the watch list; diclofenac, EE2, and E2 are included; monitoring data informs future MCL decisions.
- EU WFD EQS Directive 2013/39/EU (UK Retained)
- Sets Environmental Quality Standards for diclofenac (0.1 ug per L), EE2 (0.035 ng per L), and E2 (0.04 ng per L) in surface water; UK retained these values post-Brexit.
- COSHH Regulations 2002 (Ozone Room H2O2 Handling)
- H2O2 above 60 percent concentration is an oxidising hazard requiring a DSEAR assessment; both ozone and H2O2 storage and dosing require COSHH risk assessments and PSSR 2000 compliance.
- IED 2010/75/EU and BREF for Pharmaceutical Manufacture
- IED BAT Conclusions for pharmaceutical manufacture set effluent standards for pharmaceutical API manufacturers; hospital and pharmaceutical manufacturing wastewater pre-treatment is the primary source control for reducing river concentrations.
From the Insider